Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction

Authors:

Abstract
In 2020, esophageal cancer ranked sixth in mortality (544 100 deaths) worldwide.1,2 It consists of squamous cell carcinoma and adenocarcinoma. Esophageal and esophagogastric junction adenocarcinoma are considered a single entity, adenocarcinoma of the esophagogastric junction (AEG). The prognosis for patients with AEG undergoing upfront surgery has been poor. Five-year survival ranged from 36.9% for patients with node-negative disease to 9.6% for those with node-positive disease.2

This publication has 55 references indexed in Scilit: